Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome

Brain and Development

Volumn 22, Issue SUPPL. 1, 2000, Pages 122-131

  Saito, Yoshiaki ^a,b   Takashima, Sachio ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b Division of Pediatric Neurology   (Japan)

Author keywords

Dopamine; Lesch Nyhan syndrome; Receptor supersensitivity; Self mutilation; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; CARBIDOPA; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HOMOVANILLIC ACID; LEVODOPA; NALTREXONE; NEUROTRANSMITTER; PIMOZIDE; RISPERIDONE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

AUTOMUTILATION; BASAL GANGLION; BEHAVIOR DISORDER; CONFERENCE PAPER; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; LESCH NYHAN SYNDROME; MENTAL DEFICIENCY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY; RECEPTOR SENSITIVITY; SEROTONINERGIC SYSTEM;

EID: 0033839296     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0387-7604(00)00143-1     Document Type: Conference Paper

References (99)

1. Lesch M., Nyhan W.L. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 36:1964;561-570.
2. Rossiter B.J.F., Caskey C.T. Hypoxanthine-guanine phosphoribosyltransferase deficiency: Lesch-Nyhan syndrome and gout. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular basis of inherited disease. 7th ed :1995;1679-1706 McGraw-Hill, New York.
3. Seegmiller J.E., Rosenbaum F.M., Kelley W.N. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science. 155:1967;1682-1684.
4. Michener W.M. Hyperuricemia and mental retardation with athetosis and self-mutilation. Am J Dis Child. 113:1967;195-206.
5. Hoefnagel D., Andrew E.D., Mireault N.G., Berndt W.O. Hereditary choreoathetosis, self-mutilation and hyperuricemia in young males. N Engl J Med. 273:1965;130-135.
6. Sass J.K., Itabashi H.H., Dexter R.A. Juvenile gout with brain involvement. Arch Neurol. 13:1965;639-655.
7. Riley I.D. Gout and cerebral palsy in a three-year-old boy. Arch Dis Child. 35:1960;293-295.
8. 14C-8-iosine into uric acid, guanosine-monophosphate and adenosine-monophosphate in the liver. Tohoku J Exp Med. 95:1968;253-260.
9. Lynch B.J., Noetzel M.J. Recurrent coma and Lesch-Nyhan syndrome. Pediatr Neurol. 7:1991;389-391.
10. Mizuno T. Long-term follow-up of ten patients with Lesch-Nyhan syndrome. Neuropediatrics. 17:1986;158-161.
11. Konishi Y., Mizuno T., Kamoshita S., Endo H., Nagashima K. An autopsy case of Lesch-Nyhan syndrome. No To Hattatsu. 10:1978;327-334. in japanese.
12. Partington M.W., Hennen B.K.E. The Lesch-Nyhan syndrome: self-destructive biting, mental retardation, neurological disorder and hyperuricemia. Dev Med Child Neurol. 9:1967;563-572.
13. Watts R.W.E., Spellacy E., Gibbs D.A., AlIsop J., McKeran R.O., Slavin G.E. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Q J Med. 201:1982;43-78.
14. Christie R., Bay C., Kaufman I.A., Bakay B., Borden M., Nyhan W.L. Lesch-Nyhan disease: clinical experience with nineteen patients. Dev Med Child Neurol. 24:1982;293-306.
15. Saito Y., Hanaoka S., Fukumizu M., Morita H., Ogawa T., Takahashi K., et al. Polysomnographic studies of Lesch-Nyhan syndrome. Brain Dev. 20:1998;579-585.
16. Bakay B., Nissinen E., Sweetman L., Francke U., Nyhan W.L. Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of Lesch-Nyhan syndrome. Pediatr Res. 13:1979;1365-1370.
17. Adler C.H., Wrabetz L. Lesch-Nyhan variant: dystonia, ataxia, near-normal intelligence, and no self-mutilation. Movement Disorders. 11:1996;583-584.
18. Bassermann R., Gutensohn W., Jahn H., Springmann J.S. Pathological and immunological observations in a case of Lesch-Nyhan syndrome. Eur J Pediatr. 132:1979;93-98.
19. McCreanor G.M., Harkness R.A. Lesch-Nyhan syndrome and its pathogenesis: normal nicotineamide-adenine dinucleotide but reduced ATP concentrations that correlate with reduced poly(ADP-ribose) synthetase activity in HPRT-deficient lymphoblasts. J Inher Metab Disord. 18:1995;737-747.
20. Reed W.B., Fish C.H. Hyperuricemia with self-mutilation and choreoathetosis. Arch Derm. 94:1966;194-195.
21. Jankovic J., Caskey T.C., Stout J.T., Butler I.J. Lesch-Nyhan syndrome: a study of motor behavior and cerebral fluid transmitters. Ann Neurol. 23:1988;466-469.
22. Ernst M., Zametkin A.J., Matochik J.A., Pascualvaca D., Jons P.H., Hardy K., et al. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med. 334:1996;1568-1572.
23. Harris J.C., Lee R.R., Jinnah H.A., Wong D.F., Yaster M., Bryan R.N. Craniocerebral magnetic resonance imaging measurement and findings in Lesch-Nyhan syndrome. Arch Neurol. (55):1998;547-553.
24. Jenkins E.A., Hallet R.J., Hull R.G. Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism. Br J Rheumatol. 33:1994;392-396.
25. Watts R.W.E., Harkness R.A., Spellacy E., Taylor N.F. Lesch-Nyhan syndrome: growth delay, testicular atrophy and a partial failure of the 11β-hydroxylation of steroids. J Inher Metab Disord. 10:1987;210-223.
26. Crome L., Stern J. The pathology of mental retardation. 1st ed :1967;309-310 J & A Churchill Lyd, London.
27. Mizuno T., Endoh H., Konishi Y., Miyachi Y., Akaoka I. An autopsy case of the Lesch-Nyhan syndrome: normal HGPRT activity in liver and xanthine calculi in various tissues. Neuropaediatrics. 7:1976;351-355.
28. Saito Y., Ito M., Hanaoka S., Ohama E., Akaboshi S., Takashima S. Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neuropediatrics. 30:1999;66-71.
29. Olsen S. The brain in uremia. Acta Psychiatr Neurol Scand Suppl. 156:1961;5-128.
30. Seegmiller J.E. Discussion: pathology and pathologic physiology. Fed Proc. 27:1968;1042-1046.
31. Crussi F.G., Oberston D.M., Hiscox J.L. The pathological condition of the Lesch-Nyhan syndrome. Am J Dis Child. 118:1969;501-506.
32. Lloyd K.G., Hornykiewicz O., Davidson L., Shannak K., Farley I., Goldstein M., et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med. 305:1981;1106-1111.
33. Castells S., Chakrabarti C., Winsberg B.G., Hurwic M., Perel J.M., Nyhan W.L. Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome. J Autism Dev Disord. 9:1979;95-103.
34. Silverstein F.S., Johnston M.V., Hutchinson R.J., Edwards N.L. Lesch-Nyhan syndrome: CSF transmitter abnormalities. Neurology. 35:1985;907-911.
35. Kalsbeek A., Mattbijssen M.A.H., Uylings H.B.M. Morphometric analysis of prefrontal cortical development following neonatal lesioning of the dopaminergic mesocortical projection. Exp Brain Res. 78:1989;279-289.
36. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res. 348:1985;15-20.
37. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
38. Wichman T., Delong M.R. Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. Watts R.L., Koller W.C. Movement disorders. Neurologic principles and practice. 1997;87-97 McGraw-Hill, New York.
39. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol. 27:1990;357-365.
40. Brooks D.J., Ibanez V., Sawle G.V., Playford E.D., Quinn N., Mathias C.J., et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C] raclopride and positron emission tomography. Ann Neurol. 31:1992;184-192.
41. Graham W.C., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res. 514:1990;93-102.
42. Guttman M. Dopamine receptors in Parkinson's disease. Neurol Clin. 10:1992;377-386.
43. Rinne U.K., Laihinen A., Rinne J.O., Nagren K., Bergman J., Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Dis. 5:1990;55-59.
44. Turjanski N., Weeks R., Dolan R., Harding A.E., Brooks D.J. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 118:1995;689-696.
45. Segawa M. Body movements during sleep in dystonia of childhood. Adv Neurol Sci (Tokyo). 19:1975;743-750. in Japanese.
46. Segewa M., Nomura Y., Hikosaka O., Soda M., Usui S., Kase M. Roles of the basal ganglia and related structures in symptoms of dystonia. Carpenter M.B., Jayaraman A. The basal ganglia. 1987;489-504 Plenum Press, New York.
47. Shima F., Imai H., Segawa M. Polygraphic study on body movements during sleep in cases with involuntary movement. Rinsho Noha (Osaka). 16:1974;229-235. in Japanese.
48. Dunnett S.B., Sirinathsinghji D.J., Heavens R., Rogers D.C., Kuehn M.R. Monoamine deficiency in a transgenic (Hprt-) mouse model of Lesch-Nyhan syndrome. Brain Res. 501:1989;401-406.
49. Jinnah H.A., Wojcik B.E., Narang N., Lee K.Y., Goldstein M., Wamsley J.K., et al. Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci. 14:1994;1164-1175.
50. Yeh J., Theng S., Howard B.D. Impaired differentiation of HRPT-deficient dopaminergic neurons: a possible mechanism underlying neuronal dysfunction in Lesch-Nyhan syndrome. J Neurosci Res. 53:1998;78-85.
51. Curto R., Voit E.O., Cascante M. Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man. Biochem J. 329:1998;477-487.
52. Palmour R.M., Heshka T.W., Ervin F.R. Hypoxanthine accumulation and dopamine depletion in Lesch-Nyhan syndrome. Adv Exp Med Biol. 253A:1989;165-172.
53. Wong D.F., Harris J.C., Naidu S., Yokoi F., Marenco S., Dannals R.F., et al. Dopamine transporters are markedly reduced in Lesch-Nyhan syndrome in vivo. Proc Natl Acad Sci USA. 93:1996;5539-5543.
54. Breese G.R., Baumeister A.A., McCown T.J., Emerick S.G., Frye G.D., Mueller R.A. Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacol Biochem Behav. 21:1984;459-461.
55. Goldstein M., Kuga S., Kusano N., Meller E., Dancis J., Schwarcz R. Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: possible pharmacological model for Lesch-Nyhan syndrome. Brain Res. 367:1986;114-120.
56. Hooper M., Hardy K., Handyside A., Hunter S., Monk M. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature. 326:1987;292-295.
57. Casas-Bruge M., Almenar C., Grau I.M., Jane J., Marschitz M.H., Ungerstedt U. Dopaminergic receptor supersensitivity in self-mutilatory behavior of Lesch-Nyhan disease. Lancet. 1:1985;991-992.
58. 2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther. 240:1987;167-176.
59. Breese G.R., Criswell H.E., Duncan G.E., Mueller R.A. Dopamine deficiency in self-injurious behavior. Psychopharmacol Bull. 25:1989;353-357.
60. Simson P.E., Johnson K.B., Jurevics H.A., Criswell H.E., Napier T.C., Duncan G.E., et al. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat. J Pharmacol Exp Ther. 263:1992;1454-1463.
61. Kostrzewa R.M., Reader T.A., Descarries L. Serotonin neural adaptations to ontogenic loss of dopamine neurons in rat brain. J Neurochem. 70:1998;889-898.
62. Stauton D.A., Wolfe B.B., Groves P.M., Molinoff P.B. Dopamine receptor changes following destruction of the nigrostriatal pathway: lack of relationship to rotational behavior. Brain Res. 211:1981;315-327.
63. Carvey P.M., Kao L.C., Tanner C.M., Goetz C.G., Kiawans H.L. The effect of antimuscarinic agents on haloperidol-induced behavioral supersensitivity. Eur J Pharmacol. 12:1986;193-199.
64. Mileson B.E., Lewis M.H., Mailman R.B. Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res. 561:1991;1-10.
65. 3H-spiroperidol binding. Eur J Pharmacol. 56:1979;277-281.
66. 2 receptors in dopa-responsive dystonia and Parkinson's disease. Segawa M., Nomura Y. Age-related dopamine-dependent disorders. Monogr Neural Sci. 1995;95-100 Karger, Basel.
67. Nisenbaum L.K., Crowley W.R., Kitai S.T. Partial striatal depletion differentially affects striatal substance P and enkephalin messenger RNA expression. Mol Brain Res. 37:1996;209-216.
68. Goto S., Hirano A., Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology. 40:1990;1051-1056.
69. Sivam S.P. Dopamine, serotonin and tachykinin in self-injurious behavior. Life Sci. 58:1996;2367-2375.
70. Ferre S., Cortes R., Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci. 14:1994;4839-4846.
71. Karstaedt P.J., Kerasidis H., Pincus J.H., Meloni R., Graham J., Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol. 126:1994;25-30.
72. Luthman J., Friedemann M., Bickford P., Olson L., Hoffer B.J., Gerhardt G.A. In vivo electrochemical measurements and electrophysiological studies of rat striatum following neonatal 6-hydroxydopamine treatment. Neuroscience. 52:1993;677-687.
73. Rockson S., Stone R., van der Weyden M., Kelley W.N. Lesch-Nyhan syndrome: evidence for abnormal adrenergic function. Science. 186:1974;934-935.
74. Lake C.R., Ziegler M.G. Lesch-Nyhan syndrome: low dopamine-β-hydroxylase activity and diminished sympathetic response to stress and posture. Science. 196:1977;905-906.
75. Castro Costa M.R., Edelstein S.B., Castiglione C.M., Chao H., Breakefield X.O. Properties of monoamine oxidase in control and Lesch-Nyhan fibroblasts. Biochem Genet. 18:1980;577-590.
76. Rassin D.K., Lloyd K.G., Kelley W.N., Fox I. Decreased amino acids in various brain areas of patients with Lesch-Nyhan syndrome. Neuropediatrics. 13:1982;130-134.
77. Edwards N.L., Johnston M.V., Silverstein F.S. Cerebrospinal fluid cyclic nucleotide alterations in the Lesch-Nyhan syndrome. Adv Exp Med Biol. 253A:1989;181-184.
78. Sweetman L., Nyhan W.L. Detailed comparison of the urinary excretion of purines in a patient with Lesch-Nyhan syndrome and a control subject. Biochem Med. 4:1970;121-134.
79. Basbaum A.I., Fields H.L. Endogeneous pain control systems. Brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci. 7:1984;309-338.
80. Coid J., Alliolio B., Rees L.H. Raised plasma met-enkephalin in patients who habitually mutilate themselves. Lancet. 2:1983;545-546.
81. Sandman C.A., Barron J.L., Chicz-DeMet A., DeMet E.M. Plasma β-endorphin levels in patients with self-injurious behavior and stereotypy. Am J Ment Retard. 95:1990;84-92.
82. Kars H., Broekema W., Glaudemans-van Gelderen I., Verhoeven W.M.A., van Ree J.M. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psych. 27:1990;741-746.
83. Chernaik S.J. Opiate system in self-injurious behavior [Letter]. Am J Psychiatry. 148:1991;1421.
84. Herman B.H., Hammock M.K., Smith A.A., Egan J., Chatoor I., Werner A., et al. Naltrexone decreases self-injurious behavior. Ann Neurol. 22:1987;550-552.
85. Pellicer F., Buendia-Roldan I., Pallares-Trujillo V.C. Self-mutilation in the Lesch-Nyhan syndrome: a corporal consciousness problem? A new hypothesis. Med Hypotheses. 50:1998;43-47.
86. Origuchi Y., Miyoshino S., Mishima K., Mine K. Quantitative histologic study of the sural nerve in Lesch-Nyhan syndrome. Pediatr Neurol. 6:1990;353-355.
87. Roach E.S., Delgado M., Anderson L., Iannaccone S.T., Burns D.K. Carbamazepine trial for Lesch-Nyhan self-mutilation. J Child Neurol. 11:1996;476-478.
88. Breese G.R., Criswell H.E., Mueller R.A. Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function. Prog Neuropsychopharmacol Biol Psychatry. 14:1990;565-580.
89. Mizuno T., Yugaki Y. Prophylactic effect of L-5-hydroxytryptophan on self-mutilation in the Lesch-Nyhan syndrome. Neuropaediatrie. 6:1975;13-23.
90. Nyhan W.L., Johnson H.G., Kaufman I.A., Jones K.L. Serotonergic approaches to the modification of behavior in the Lesch-Nyhan syndrome. Appl Res Ment Retard. 1:1980;25-40.
91. Anders T.F., Cann H.M., Ciaranello R.D., Barchas J.D., Berger P.A. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Neuropediatrie. 9:1978;157-166.
92. Allen S.M., Rice S.N. Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient. Prog Neuropsychopharmacol Biol Psychiatry. 20:1996;793-800.
93. Allen S.M., Freeman J.N., Davis W.M. Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome. Pharmacol Biochem Behav. 59:1998;327-330.
94. 2 receptor subtype mRNAs in rat brain. J Comp Neurol. 351:1995;357-373.
95. Ferre S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interaction as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
96. Criswell H., Mueller R.A., Breese G.R. Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine. J Pharmacol Exp Ther. 244:1988;493-500.
97. Giliman M.A., Sandyk R. Opiatergic and dopaminergic function and Lesch-Nyhan syndrome. Am J Psychiatry. 142:1985;1226.
98. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Brain. 116:1993;433-452.
99. Cooper S.J., Dourish C.T. An introduction to the concept of stereotypy and a historical perspective on the role of brain dopamine. Cooper S.J., Dourish C.T. Neurobiology of stereotyped behavior. 1990;1-24 Oxford University Press, New York.